Abstract
AbstractHuman Cytomegalovirus (hCMV) related pneumonia is mainly known as a potentially severe end organ disease in immunocompromised patients. However, hCMV lung reactivation can also alter the prognosis of critically ill patients, irrespective of their initial immune status. In this review, we focus on the epidemiology, physiopathology, diagnostic tools and clinical aspects of hCMV related pneumonia. We also summarize therapeutic strategies with an update on the old and new molecules to consider. Conclusion open up on research perspectives concerning the virus’s physiopathology such as SARS-CoV-2 and CMV virusvirus interactions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
